DOSAGE INDEX / SINGLE
Tirzepatide
Research, reported schedules and supply planning.
Explore tirzepatide trials for weight loss, diabetes and sleep apnea, direct semaglutide comparisons, maintenance evidence and current safety information.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 2.5 mg weekly initially, then 5 mg; the source describes optional 2.5 mg increments at intervals of at least four weeks, up to 15 mg
- Frequency
- Once weekly
- Cycle / observation period
- Four-week minimum dose stages; maintenance is indication-dependent
- Route / research model
- Subcutaneous
A research powder is not equivalent to an approved ready-to-use injection. This summary does not validate powder preparation or treatment eligibility.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–28 | 2.5 mg | Weekly |
| Days 29–56 | 5 mg | Weekly |
Compare the product label or clinical-study schedule
Adults meeting Zepbound weight-management eligibility, or adults with obesity and moderate-to-severe obstructive sleep apnea.
The Zepbound label begins with 2.5 mg subcutaneously once weekly for four weeks, then 5 mg weekly. Further increases are in 2.5 mg steps after at least four weeks at the current dose. Weight-management maintenance doses are 5, 10 or 15 mg weekly; sleep-apnea maintenance is 10 or 15 mg weekly. The maximum is 15 mg weekly. The starting 2.5 mg dose is not a maintenance dose.
Dose selection depends on response and tolerability. Contraindications include personal/family medullary thyroid carcinoma or MEN 2. The full label covers serious gastrointestinal effects and additional risks.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
The approved product is supplied as a prepared solution, with no user reconstitution. Its handling instructions do not establish a diluent for a separately supplied research powder.
Vial comparison
Initial 8 weeks only; subsequent maintenance is not included: 30 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 5 mg | 6 |
| 10 mg | 3 |
| 15 mg | 2 |
| 30 mg | 1 |
| 40 mg | 1 |
| 50 mg | 1 |
| 60 mg | 1 |
| 80 mg | 1 |
| 90 mg | 1 |
| 100 mg | 1 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- SURMOUNT-1 randomized 2,539 adults with obesity or overweight and a related complication, excluding diabetes. Over 72 weeks, mean weight changes were -15.0%, -19.5% and -20.9% for the 5, 10 and 15 mg tirzepatide trial arms, versus -3.1% with placebo. Gastrointestinal events were the most common adverse events and were generally mild or moderate. Adverse-event discontinuation occurred in 4.3%, 7.1% and 6.2% of the tirzepatide arms, versus 2.6% with placebo. [1]
- Two randomized trials reported that tirzepatide reduced the apnea-hypopnea index compared with placebo in adults with moderate-to-severe obstructive sleep apnea and obesity. The primary comparison was measured at 52 weeks. [2]
- Mounjaro carries a boxed warning for thyroid C-cell tumors observed in rats; human relevance is unknown. Personal or family medullary thyroid carcinoma and MEN2 are contraindications. Warnings include pancreatitis, severe gastrointestinal reactions, gallbladder disease, dehydration-related kidney injury, hypoglycemia with certain diabetes medicines, retinopathy complications and aspiration during anesthesia or deep sedation. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 100 entries mapped from 10 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original SURMOUNT-1 trial
- Original sleep-apnea trial publication
- Mounjaro prescribing information
- DailyMed (2026): Zepbound tirzepatide injection: current prescribing information and weekly escalation scheduleRegulatory / product information · Listed in reference bibliography.
- ClinicalTrials.gov: SURMOUNT-1 study record NCT04184622Trial registry · Listed in reference bibliography.
- The Lancet (2021): SURPASS-1 randomized phase 3 tirzepatide monotherapy trialFurther reading · Listed in reference bibliography.
- New England Journal of Medicine (2024): Tirzepatide for obesity treatment and diabetes prevention: three-year SURMOUNT-1 findingsFurther reading · Listed in reference bibliography.
- FDA: Zepbound tirzepatide injection prescribing informationRegulatory / product information · Listed in reference bibliography.
- Nature Medicine (2022): Tirzepatide cardiovascular risk factors and safety in type 2 diabetes: SURPASS program analysisFurther reading · Listed in reference bibliography.
- The Lancet Diabetes and Endocrinology (2023): Tirzepatide for chronic weight management: SURMOUNT clinical development program designFurther reading · Listed in reference bibliography.
- CDC: Preventing unsafe injection practices and handling multidose vialsGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf: Best practices for injections and related proceduresFurther reading · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.